Alnylam Pharmaceuticals’ (ALNY) “Outperform” Rating Reiterated at William Blair

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “outperform” rating restated by equities research analysts at William Blair in a report released on Wednesday,RTT News reports.

Several other equities analysts also recently issued reports on ALNY. Raymond James lifted their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday. Barclays upped their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Piper Sandler restated an “overweight” rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Finally, HC Wainwright increased their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Monday. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $304.26.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY traded up $4.11 during trading hours on Wednesday, hitting $249.31. 253,921 shares of the company traded hands, compared to its average volume of 696,054. The firm has a 50-day moving average of $254.21 and a 200 day moving average of $262.72. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39. The stock has a market capitalization of $32.28 billion, a price-to-earnings ratio of -114.99 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CMO Pushkal Garg sold 1,752 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the sale, the chief marketing officer now owns 15,705 shares of the company’s stock, valued at $3,941,955. This represents a 10.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 72,986 shares of company stock valued at $20,397,849 in the last 90 days. 1.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Huntington National Bank increased its stake in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 45 shares in the last quarter. Larson Financial Group LLC boosted its stake in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares during the period. Hollencrest Capital Management bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. R Squared Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $33,000. Finally, OFI Invest Asset Management bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $35,000. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.